The nanoemulsion market is anticipated to register a CAGR of 8.6% during the forecast period.
Vaccines are believed to play a significant role in the treatment of several chronic diseases, which gained more prevalence in recent decades. An increasing number of biopharmaceutical companies are being attracted to the use of nanoemulsion formulation in the development of the vaccine. The last decade showed several promises, with successful results of nanoemulsion being used as adjuvants for vaccines, treating chronic infections and cancer diseases through targeted therapies. Increasing research projects through institutes, in collaboration with various government funds and companies, are being witnessed, which primarily deals with the improvement of the oral delivery of drugs for the management of chronic diseases. The nanoemulsion provides enhanced transdermal permeation of drugs, which, in turn, increases the plasma concentration profiles and bioavailability of the drug. In the case of cancer indications, the nanoemulsion and nanoparticle form offers a higher potential of killing the cancer cells, as well as better treatment of cancer, osteoarthritis, and fibromyalgia, among others. With the constant demand for new and improved vaccines, nanoemulsion applications are expected to rise, globally, and drive the market.
Key Market Trends
Antibiotics is Expected to Register Healthy CAGR in the Application Segment, Over the Forecast Period
There is a rising interest in the application of nanoemulsion in antimicrobial properties and be effective anti-biofilm agents. The rising antibiotic resistance has received increased attention from researchers and companies across the world. However, the rate of new antibiotics released in the market for therapeutic treatment against emerging “superbugs” has been low. An increasing number of research articles were published in the Asian Journal of Pharmaceutical Education and Research, 2018, on nanoemulsions in antibacterial properties, such as stability and antibacterial properties of erythromycin oil-in-water nanoemulsion against Staphylococcus aureus, Pseudomonas Aeruginosa, and Streptococcus pneumonia. With applications in a wide range of antibiotics for several diseases and better treatment possibilities, the companies that invest in this segment are steady. Thus, the success rate and adoption may further determine the growth and challenges for this segment, over the forecast period.
North America is Expected to Dominate the Market Over the Forecast Period
North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of chronic diseases in the region, established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. In this region the United States has the maximum share due to supportive healthcare policies, the high number of patients, and a developed healthcare market.
The nanoemulsion market is competitive and consists of a few major players and several small players. In terms of market share, the major players, namely, Ascendia Pharmaceuticals, Covaris Inc., Microfluidics (IDEX Corporation), Taiwan Liposome Company Ltd, and Allergan PLC, among others, currently dominate the market.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support